• FP Essentials™ 

    Less Common Respiratory Conditions

    #502 Edition | March 2021

    FP Essentials is a monthly subscription containing authoritative and peer-reviewed clinical information—without any advertisements.

    Purchase this individual edition for online access to its content, and earn up to 5 CME credits upon completion of the quiz. Online access for this edition and CME credit available until March 15, 2023.

    FP Essentials #502 Cover

    Already Purchased? Access Now

    Online access and CME credit for this edition are available until March 15, 2023. Purchasers can access the content below after logging in.

    Foreword
    Occupational Lung Diseases
    Sarcoidosis
    Fungal Respiratory Infections
    Pulmonary Tuberculosis

    Download Edition as a PDF
    Take the CME Quiz

    Access your editions in the AAFP app. You may also try a free digital sample.

    In This Edition

    • Routinely ask patients with pulmonary symptoms about not only their current occupation, but also past occupations to determine if the symptoms might be related to an occupational lung disease.
    • Evaluate for the common occupational lungs diseases when those diseases are sus­pected based on history and examination findings.
    • Summarize diagnostic criteria from the most current sarcoidosis guidelines.
    • Describe guideline-recommended sarcoidosis treatment for patients in whom treatment is indicated. Describe appropriate monitoring for patients not requiring treatment to detect disease progression.
    • Consider coccidioidomycosis when evaluating what otherwise appears to be community-acquired pneumonia in patients who have visited or live in endemic areas.
    • Consider allergic bronchopulmonary aspergillosis as a cause of coughing/wheezing in patients with asthma or cystic fibrosis.
    • Identify individuals at risk for latent tuberculosis and perform appropriate screen­ing in such individuals.
    • Summarize management of latent tuberculosis with the new short-duration drug regimens that have replaced the long-standing standard therapy of 9 months of daily isoniazid.
       

    Purchase This Edition 

    Online access only

    #502: Less Common Respiratory Conditions
    March 2021

    Member: $39.95
    Nonmember: $44.95


    Note: the price you will see in the cart will be the price you will pay.